Multimodality Therapy for Stage Iii Nsclc: Controversies, Advances, and Evolving Approaches

Abstract

Stage III non-small cell lung cancer (NSCLC) comprises a very heterogenous group of patients with regard to tumor extent, prognosis, and treatment options. Although combined-modality therapy (chemotherapy ± radiotherapy ± surgery) is appropriate in most patient subsets, specific recommendations vary considerably. For example, concurrent chemoradiotherapy… (More)

Topics

2 Figures and Tables